ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0074

The Intracellular DNA Sensor STING Protects Against Bone Loss Through Regulation of Type I Interferons

Susan MacLauchlan1, Catherine Manning2, Sijia Chen3, Katherine Fitzgerald4, Shruti Sharma5 and Ellen Gravallese1, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women’s Hospital, Boston, 3Brigham and Women's Hospital, Boston, 4University of Massachusetts medical school, Worcester, MA, 5Tufts University, Boston, MA

Meeting: ACR Convergence 2020

Keywords: bone biology, innate immunity, interferon, osteoclastogenesis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Innate Immunity Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The intracellular DNA sensor Stimulator of Interferon Genes (STING) is essential for detection of viral and bacterial pathogen DNA. As with other pathways in the innate immune system, hyperactivation of the STING pathway is associated with autoinflammatory and autoimmune diseases. Activation of STING promotes anti-viral responses through production of type I interferons, including IFNβ. A pleiotropic cytokine, IFNβ is a potent stimulus of the innate immune system and has also been shown to inhibit the formation of osteoclasts. We therefore sought to determine whether the STING pathway impacts bone homeostasis and osteoclastogenesis.

Methods: Osteoclast formation assays were performed using RANKL-stimulated bone marrow progenitors from STING deficient (KO) mice and myeloid-specific STING KOs.  The immortalized myeloid cell line RAW294.7 was engineered to stably overexpress murine STING or an empty vector control. RANKL was used to stimulate osteoclast precursors to form osteoclast-like cells in vitro.  Secreted IFNβ was monitored using ELISA.  IFNβ activity was inhibited using an IFNaR1 blocking antibody (Biolegend).  Trabecular and cortical bone parameters were determined in femurs from aging (6, 13, and 15 months) STING whole body KO mice and littermate controls using microCT. Ovariectomies in myeloid-specific-STING KOs (STINGflox/flox LysM+/-, hereafter referred to STINGLysM KO) and littermate controls (STINGflox/flox LysM-/-), were performed in young female mice and bone parameters were evaluated by microCT 8 weeks after surgery.

Results: Osteoclast differentiation assays demonstrate that young STING KO bone marrow progenitors develop into osteoclasts faster than littermate controls. This phenotype of increased osteoclast formation is sustained in progenitors from aged (6 month old) STING KO mice. The STINGLysM KO precursor cells recapitulate the osteoclast formation phenotype of STING KO cells in vitro. A reciprocal effect is observed in RANKL-stimulated RAW294.7 cells overexpressing STING, where fewer osteoclast-like cells are generated compared to RAW294.7 cells containing an empty vector.  STING overexpressing RAW294.7 cells produce more IFNβ than empty vector controls, and blocking IFNaR1 downstream of IFNβ limited osteoclast formation in STING over expressing RAW294.7 cells. To determine the role of STING for bone turnover in vivo, microCT was used to characterize bone in aging cohorts of STING KO mice.  Consistent with these in vitro observations, STING KO mice lose trabecular bone faster than wildtype (WT) littermate controls.  Myeloid STING is sufficient for enhanced bone turnover, as ovariectomized STINGLysM KO mice exhibit a larger decrease in trabecular bone compared to littermate controls. 

Conclusion: Our results are the first to implicate any of the cytosolic DNA sensors in the maintenance of bone. We demonstrate thatincreased STING activity limits osteoclast formation, an effect which is mediated at least in part by IFNβ.  Moreover, loss of STING activity results in accelerated bone loss.  These data suggest that STING activation plays an important role inthe protection from bone loss in the settings of viral infection and inflammation in inflammatory rheumatic diseases. 


Disclosure: S. MacLauchlan, None; C. Manning, None; S. Chen, None; K. Fitzgerald, None; S. Sharma, None; E. Gravallese, New England Journal of Medicine, 3, UpToDate, 7, Co-editor of the textbook Rheumatology, 7.

To cite this abstract in AMA style:

MacLauchlan S, Manning C, Chen S, Fitzgerald K, Sharma S, Gravallese E. The Intracellular DNA Sensor STING Protects Against Bone Loss Through Regulation of Type I Interferons [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/the-intracellular-dna-sensor-sting-protects-against-bone-loss-through-regulation-of-type-i-interferons/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-intracellular-dna-sensor-sting-protects-against-bone-loss-through-regulation-of-type-i-interferons/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology